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Abstract
Chemotherapy is a general treatment option for various cancers, including lung cancer. In order to 
find compounds with superior bioactivity and less toxicity against lung cancer, novel spin-labeled 
5-fluorouracil (5-FU) derivatives (3a–f) were synthesized and evaluated against four human tumor 
cell lines (A-549, DU-145, KB, and KBvin). Two promising compounds 3d and 3f exhibited IC50 
values of 2.76 and 2.38 μM, respectively, against non-small cell lung carcinoma cell line A-549. 
These compounds were twofold more cytotoxic than 5-FU and less toxic against other tested cell 
lines. Compound 3f exhibited seven times more selective cytotoxicity against A-549 than 5-FU. 
Our results suggest that compounds 3d and 3f merit further investigation for development into 
clinical trial candidates for non-small cell lung cancer.
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Introduction
5-Fluorouracil (5-FU, 1) is a widely used clinical treatment for solid tumors, such as 
colorectal, breast, liver, gastric, and other cancers. 5-FU is used as a combination 
chemotherapy for lung cancer (Ghoshal and Jacob, 1997; Huang et al., 2007; Isanbor and 
O’Hagan, 2006). As an antimetabolite, 5-FU was first synthesized in 1957 (Heidelberger et 
al., 1957). It is a pyrimidine analogue of DNA and RNA, with a fluorine atom at the C-5 
position in place of the hydrogen of uracil (Zhang et al., 2008). 5-FU is an irreversible 
inhibitor of thymidylate synthetase and consequently interferes with the formation of 
thymidylic acid from deoxyuridylic acid to inhibit DNA synthesis. As a uracil analogue, 5-
FU may be incorporated into RNA to give an aberrant form of RNA, leading to cytotoxicity 
and cell death (Bosch et al., 1958; Cohen et al., 1958; Goldberg et al., 1966; Madoc-Jones 
and Bruce, 1968; Kufe and Major, 1981). However, 5-FU is poorly selective toward tumors, 
and it causes some undesirable side effects, such as gastrointestinal tract reaction, bone 
marrow depression, dermatologic changes, alopecia, leucopenia, thrombocytopenia, 
neurotoxicity, cardiotoxicity, and even death (Kennedy, 1999). These side effects have 
interfered significantly with 5-FU’s clinical application. Accordingly, it is necessary to 
continuously design and synthesize 5-FU analogues that have broad-spectrum or selective 
antineoplastic activities and can overcome the clinical limitations.
Furthermore, the introduction of a stable nitroxyl radical into a pharmaceutical molecule 
can, to some extent, reduce toxicity and augment antineoplastic activities (Gadjeva, 2002; 
Jin et al., 2006; Zheleva and Gadjeva, 2001). In our previous studies, we successfully 
prepared several series of spin-labeled antineoplastic drugs by modifying different bioactive 
molecules. When compared with the parent compounds, many of the spin-labeled 
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compounds showed significant antineoplastic activity with markedly decreased toxicity (Liu 
et al., 2007, 2012; Liu and Tian, 2005; Tian et al., 2002; Wang et al., 1993). In addition, L-
amino acids are actively transplanted into mammalian tissue, have good water solubility, 
and are often used as carrier vehicles for some drugs. Based on the above facts, we 
introduced the nitroxyl radical moiety into 5-FU via a hydrophilic amino acid spacer, in an 
attempt to simultaneously circumvent 5-FU’s limitations and develop superior 
pharmacological profiles. Herein, we report the synthesis and structure–cytotoxicity 
relationships of a series of novel spin-labeled derivatives of 5-FU as potential antitumor 
agents.
Results and discussion
Design and synthesis of novel 5-FU analogues
The synthetic route to the N-(1-oxyl-2,2,6,6-tetramethyl-4-piperidinyloxycarbonyl)-amino 
acids 9a–f is depicted in Scheme 1. 4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (5) was 
synthesized in 83 % yield by catalytic oxidation of 4-hydroxy-2,2,6,6-tetramethylpiperidine 
(4) with sodium tungstate–hydrogen peroxide–EDTA (Rozantsev, 1964). The reaction of 5 
with N,N-carbonyldiimidazole gave N-(1-oxyl-2,2,6,6-tetramethylpiperidinyloxycarbonyl)-
imidazole (6) (Staab and Mannschreck, 1962). Without purification, this intermediate (6) 
was reacted with p-toluenesulfonic acid monohydrate to give a highly reactive tosylate (7). 
When dissolved in an aqueous solution of sodium azide, 7 was converted instantaneously 
into the alkoxycarbonyl azide (8). Compounds 9a–f were obtained in good yields by 
reaction of 8 with the appropriate amino acids in the presence of MgO (Hankovszky et al., 
1979).
Subsequently, commercially available 5-FU (1) was heated with 37 % aqueous 
formaldehyde for about 50 min at 60 °C to yield 1-hydroxymethyl-5-fluorouracil (2) 
(Ahmad et al., 1987; Ouyang et al., 2011). The target esters 3a–f were obtained in excellent 
yields by the straightforward acylation of intermediate 2 with the corresponding N-(1-
oxyl-2,2,6,6-tetramethyl-4-piperidinyloxycarbonyl)-amino acids 9a–f in the presence of 
N,N-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) (Scheme 2). 
The presence of the nitroxide group in the target compounds 3a–f was confirmed from ESR 
and IR spectra. In the ESR spectra, the nitroxide group showed a triplet with hyperfine 
coupling constants (aN) in the range of 15.90–16.28 G due to interaction between an 
unpaired electron and nitrogen nucleus of the aminoxyl radical (g value = 2.006). In the IR 
spectra, bands characteristic of the nitroxyl moiety appeared at 1,370 ± 7 cm−1 as shown in 
Table 1. Furthermore, melting point and high-resolution mass spectrometry (ESI) data also 
characterized the target compounds 3a–f (Table 1).
Effects of novel 5-FU analogues on tumor cell growth
Target compounds 3a–f were evaluated for in vitro cyto-toxicity against four tumor cell 
lines, human alveolar adenocarcinoma (A-549), human prostate carcinoma (DU-145), 
human nasopharyngeal carcinoma (KB), and human vincristine-resistant nasopharyngeal 
carcinoma (KBvin). The parent compound 5-FU (1) was included as a positive control, and 
the obtained IC50 values are shown in Table 2. The selectivity index (SI) against A-549 was 
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calculated as mean IC50 against DU-145, KB, and KBvin divided by IC50 against A-549. 
Our results demonstrated that 3f showed the best SI (7.5) against A-549.
5-FU and its spin-labeled derivatives showed the same order of cell line sensitivity: A-549 > 
DU-145 > KB > KBvin (decreasing potency of test compound). Against the A-549 cell line, 
compounds 3d and 3f, with IC50 values of 2.762 and 2.38 μM, respectively, were twofold 
more potent than 5-FU, with an IC50 value of 5.09 μM. Furthermore, these compounds 
exhibited good selectivity against A-549, suggesting less toxicity for normal cells. Against 
the DU-145, KB, and KBvin cell lines, compound 3e, with IC50 values of 11.36, 11.60, and 
11.71 μM, respectively, was as or slightly more potent than 5-FU, with IC50 values of 10.97, 
12.79, and 13.70, respectively. Against the indicated cell lines, the rank orders of activity 
based on the different amino acid linkages were as follows: for A-549, L-proline > L-
phenylalanine > L-methionine > L-leucine > L-alanine > L-valine; for DU-145, L-
methionine > L-leucine > L-phenylalanine > L-proline > L-alanine > L-valine; for KB L-
methionine > L-leucine > L-phenylalanine > L-proline > L-valine ≥ L-alanine; and for 
KBvin, L-methionine > L-leucine > L-phenylalanine > L-valine ≥ L-proline ≥ L-alanine. 
These results showed that the structures of the L-amino acids can have potential effects on 
the bioactivity of these compounds.
Thus, we have successfully introduced a stable nitroxyl radical into 5-FU via an L-amino 
acid linkage. Based on the cytotoxicity results, this modification might result in synergistic 
action against certain tumor cell lines. Further biological evaluation is in progress to better 
define the antineoplastic activity of these compounds and to clarify whether spin-labeled 5-
FU analogues might display decreased side effects compared with 5-FU.
Conclusion
We have synthesized novel spin-labeled derivatives of 5-FU and evaluated their cytotoxic 
effects against four tumor cell lines by the SRB method. Among all tested compounds, 
compounds 3d and 3f were more cytotoxic than 5-FU against the A-549 lung cancer cell line 
and merit further investigation for development into clinical trial candidates against non-
small cell lung cancer.
Experimental
Chemistry
Melting points were taken on a Kofler melting point apparatus and uncorrected. IR spectra 
were obtained on NIC-5DX spectra photometer, mass spectral analysis was taken on ZAB-
HS and Bruker Daltonics APEXII49e instruments, and ESR spectra were obtained with a 
Bruker ER-200D-SRC X-band spectrometer. The synthetic compounds were purified by 
flash chromatography on Merck silica gel (70–230 mesh). Thin-layer chromatography 
(TLC) was performed on silica gel plates with a fluorescent indicator (Merck Silica Gel 60 
F2540.25 mm thick). The N-(1-oxyl-2,2,6,6-tetramethyl-4-piperidinyloxycarbonyl)-amino 
acids (9a–f) (Hankovszky et al., 1979) and 1-hydroxymethyl-5-fluorouracil used for the 
experiments were prepared by modifications of previous procedures (Ahmad et al., 1987; 
Ouyang et al., 2011).
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General procedure for the synthesis of target compounds (3a–f)
A mixture of a N-(1-oxyl-2,2,6,6-tetramethyl-4-piperidinyloxycarbonyl)-amino acid (0.001 
M), 1-hydroxymethyl-5-fluorouracil (0.001 M), and dimethylaminopyridine (DMAP, 0.1 g) 
was stirred in dichloromethane (10 mL) for 5 min at room temperature under nitrogen. N,N-
Dicyclohexylcarbodiimide (DCC, 0.21 g, 0.001 M) was added, and the reaction mixture was 
stirred for 2 h. The reaction mixture was filtered, and the filtrate was evaporated under 
reduced pressure. The residue was separated by flash column chromatography (gradient 
elution with mixtures of dichloromethane–acetone) on silica gel and monitored by TLC. 
Synthesized target compounds 3a–f were characterized by m.p., ESR, IR, and HRMS 
spectroscopic analyses.
Cell culture and determination of cytotoxic activity
A-549 (non-small cell lung carcinoma), DU145 (androgen-independent prostate cancer), and 
KB (nasopharyngeal carcinoma) cell lines were obtained from the Lineberger 
Comprehensive Cancer Center (UNC-CH). KBvin (vincristine-resistant KB) cell line was a 
generous gift of Professor Y.-C. Cheng, Yale University. Cells were cultured in RPMI 1640 
medium containing 25 mM HEPES and 2 mM L-glutamine (Mediatech), supplemented with 
10 % heat-inactivated fetal bovine serum (Hyclone), 100 IU penicillin, 100 μg/mL 
streptomycin, and 0.25 μg/mL amphotericin B (Mediatech) in 5 % CO2 and 95 % air at 37 
°C.
Antiproliferative activity was determined by the sulfo-rhodamine B (SRB) colorimetric 
assay as previously described (Nakagawa-Goto et al., 2011). In brief, cells (3–5 × 103 cells/
well) were seeded in 96-well plates filled with culture medium containing various 
concentrations of sample and incubated for 72 h. At the end of the exposure period, cells 
were fixed with cold 50 % trichloroacetic acid followed by staining with 0.04 % SRB 
(Sigma Chemical Co.). The absorbance of solubilized SRB was measured at 515 nm on a 
Microplate Reader ELx800 (Bio-Tek Instruments, Winooski, VT) with Gen5 software. All 
results are representative of three or more experiments.
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Synthesis of compounds 9a–f. Reagents and conditions: i Na2WO4/H2O2/EDTA; ii N,N′-
carbonyl-diimidazole/THF; iii p-toluenesulfonic acid monohydrate; iv NaN3/H2O; v amino 
acids/MgO, 24 h
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Synthesis of target compounds 3a–f. Reagents and conditions: i HCHO; ii 9a–f/DCC/
DMAP, 2 h
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